Five-year Treatment with Tenofovir Alafenamide Achieves High Rates of Viral Suppression, Alanine Aminotransferase Normalization, and Favorable Bone and Renal Safety in Chinese Chronic Hepatitis B Patients
Jinlin Hou(Southern Medical University), Jidong Jia(Beijing Friendship Hospital), Roberto Mateo(Gilead Sciences (United States)), Tahmineh Yazdi(Gilead Sciences (United States)), Leland J. Yee(Gilead Sciences (United States)), Guozhong Gong(Central South University), Frida Abramov(Gilead Sciences (United States)), John F. Flaherty(Gilead Sciences (United States)), Lunli Zhang(Nanchang University), Shelley Xie(Gilead Sciences (United States)), Qing Xie(Ruijin Hospital), Mingxiang Zhang(Chinese Academy of Medical Sciences & Peking Union Medical College), Jun Li(Xuzhou Medical College), Yongfeng Yang(Shenyang Agricultural University), Yu Chen(Memorial Sloan Kettering Cancer Center), Qin Ning(Tongji Hospital), Hongyuan Wang(Gilead Sciences (United States)), Chengwei Chen(302 Military Hospital of China), Hong Tang(Sichuan University), Zhongping Duan(Capital Medical University), Shanming Wu(Shanghai Public Health Clinical Center), Feng Lin(Michigan State University), Yanwen Luo(Unilever (China)), Yan Huang(Central South University)
Cited by 7
Related Papers
Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission
|The Lancet. Gastroenterology & hepatology|2019|539
Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study
|The Lancet. Gastroenterology & hepatology|2023|399
aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis
|Journal of Hepatology|2020|346
Guideline of Prevention and Treatment for Chronic Hepatitis B (2015 Update)
|Journal of Clinical and Translational Hepatology|2017|277
Efficacy and Safety of Bepirovirsen in Chronic Hepatitis B Infection
|New England Journal of Medicine|2022|264